FLT3 and acute myeloid leukemia: Gilteritinib is an orally available FDA-approved drug used for the treatment of patients with acute myeloid leukaemia (AML) harboring FMS-like tyrosine kinase 3 (FLT3) mutation (Dhillon, 2019; Levis and Perl, 2020).